MEK1 VUS validation experiments

CB Craig M. Bielski
MD Mark T.A. Donoghue
MG Mayur Gadiya
AH Aphrothiti J. Hanrahan
HW Helen H. Won
MC Matthew T. Chang
PJ Philip Jonsson
AP Alexander V. Penson
AG Alexander Gorelick
CH Christopher Harris
AS Alison M. Schram
AS Aijazuddin Syed
AZ Ahmet Zehir
PC Paul B. Chapman
DH David M. Hyman
DS David B. Solit
KS Kevin Shannon
SC Sarat Chandarlapaty
MB Michael F. Berger
BT Barry S. Taylor
request Request a Protocol
ask Ask a question
Favorite

MEK1 mutant constructs were generated from the C-terminal GFP-tagged MEK1 plasmid (pEGPF-N1-MEK1, Addgene, #14746) using the QuikChange II XL Site-Directed Mutagenesis Kit (Stratagene) and verified by Sanger sequencing. HEK-293H cells were transiently transfected with the wild-type or mutant MEK1-GFP plasmid using Lipofectamine® 2000 Transfection Reagent (Invitrogen). At 24 hr post-transfection, media was aspirated and refreshed for 1 hr at which time cells were harvested, lysed in 1% NP-40 buffer with protease and phosphatase inhibitors, protein quantified, and processed for immunoblotting. Rabbit polyclonal antibodies recognizing phosphorylated MEK1/2 (Ser217/221), MEK1/2, phosphorylated ERK1/2 (Thr202/Tyr204), and ERK1/2 were obtained from Cell Signaling. Rabbit monoclonal antibodies recognizing GFP and GAPDH were obtained from Cell Signaling. After incubation with horseradish peroxidase-conjugated secondary antibody, proteins were detected by chemiluminescence (SuperSignal West Pico Plus Chemiluminescent Substrate, Thermo Scientific) and visualized using the Fuji LAS-4000 imager (GE Life Sciences).

Do you have any questions about this protocol?

Post your question to gather feedback from the community. We will also invite the authors of this article to respond.

post Post a Question
0 Q&A